RRML - LSM3, NDUFB3, and PTGS2 may be potential biomarkers for BRCA1-mutation positive breast cancer
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- December 2020 -
 
Assessment of circulating tumo... 3
Antibacterial and antitumor ac... 2
Molecular epidemiology and the... 2
Romanian Review of Laboratory ... 1
The role of neutrophil to lymp... 1
A rare case of acute myeloid l... 1

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 28(4)/2020 DOI:10.2478/rrlm-2020-0037
XML
TXT

Research article

LSM3, NDUFB3, and PTGS2 may be potential biomarkers for BRCA1-mutation positive breast cancer

Kang Hu, Fengjiao Gan, Xue Wang, Lin Xu, Qiaoyuan Wu, Ni Jiang, Suhong Sun

Correspondence should be addressed to: Suhong Sun

Abstract:

Purpose: We aimed to find critical biomakers associated with BRCA1-mutation positive breast cancer. Methods: The data set E-MTAB-982 was downloaded from ArrayExpress database and the data were preprocessed using R package Oligo. Differential expression analysis between BRCA1-mutation positive breast cancer patients and BRCA1-mutation positive healthy subjects were performed using limma package. Then, gene set enrichment analysis was conducted. We constructed the network for BRCA1, its related differentially expressed genes (DEGs), and the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. After that, survival analysis was performed based on the clinical data of breast cancer in TCGA database. Finally, box diagram for key genes was drawn. Results: The network showed that LSM3, NDUFB3, GNPDA2, and PTGS2 were BRCA1 related DEGs. Furthermore, LSM3 was mainly enriched in RNA degradation pathway and spliceosome pathway. PTGS2 was enriched in arachidonic acid metabolism and VEGF signaling pathway. Survival analysis indicated that high expression of LSM3 indicated a poor prognosis of BRCA1-mutant breast cancer. Besides, box diagram showed that LSM3 was down-regulated in BRCA1-mutation positive breast cancer patients compared with that in BRCA1-mutation positive healthy subjects. Conclusions: LSM3, NDUFB3, and PTGS2 may be biomarkers in BRCA1-mutant breast cancer, and high expression of LSM3 may indicate a poor prognosis of BRCA1-mutant breast cancer.

Keywords: BRCA1-mutation; breast cancer; differentially expressed genes; pathways

Received: 23.7.2020
Accepted: 28.10.2020
Published: 31.10.2020

 
  PDF Download full text PDF
(1331 KB)
     
 
How to cite
Hu K, Gan F, Wang X, Xu L, Wu Q, Jiang N, et al. LSM3, NDUFB3, and PTGS2 may be potential biomarkers for BRCA1-mutation positive breast cancer. Rev Romana Med Lab. 2020;28(4):381-91. DOI:10.2478/rrlm-2020-0037